Severe acute respiratory syndrome coronavirus 2 Beta variant Spike protein (SARS-CoV-2 Beta S protein)

The SARS-CoV-2 Beta variant antigens primarily consist of the mutated Spike (S) protein characteristic of the B.1.351 lineage of the virus, which first emerged in South Africa [1, 2]. This viral surface glycoprotein is essential for the infection process, as it mediates the attachment of the virus to the host cell's angiotensin-converting enzyme 2 (ACE2) receptor and facilitates subsequent membrane fusion and entry [7, 19]. The Beta variant is distinguished by a specific constellation of mutations in its receptor-binding domain (RBD), most notably K417N, E484K, and N501Y, which together enhance receptor affinity and drive significant escape from neutralizing antibodies [3, 10, 18]. These antigens are the primary targets for COVID-19 vaccines and therapeutic monoclonal antibodies designed to neutralize the virus and prevent disease [13, 16]. However, the presence of the E484K 'escape' mutation has posed a significant therapeutic challenge, as it reduces the neutralizing potency of several early-generation monoclonal antibodies and can lower the efficacy of primary series vaccines [5, 8, 14]. Clinical management involves continuous genomic surveillance of these antigens to ensure that prophylactic and therapeutic interventions remain effective against the evolving viral landscape [10, 20].

Other names

B.1.351 Spike protein501Y.V2 Spike proteinSARS-CoV-2 B.1.351 antigenSouth African variant antigensVOC-202012/02 Spike

Neutralizing monoclonal antibodies and vaccine-induced antibodies target the Spike protein's receptor-binding domain (RBD) or N-terminal domain (NTD), physically blocking its interaction with the host ACE2 receptor and preventing viral entry into host cells.